The prescribing pattern of a new antipsychotic: A descriptive study of aripiprazole for psychiatric in-patients

Basic and Clinical Pharmacology and Toxicology

Volumn 103, Issue 1, 2008, Pages 75-81

  Andersen, Stig Ejdrup ^a   Johansson, Majka ^b   Manniche, Charlotte ^b  

^a BISPEBJERG HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; AGITATION; ANXIETY; ARTICLE; CATATONIA; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; HUMAN; HYPERACTIVITY; HYPOTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUSCLE RIGIDITY; NAUSEA AND VOMITING; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; SCHIZOPHRENIA; SIDE EFFECT; SKIN DISEASE; TACHYCARDIA; TREATMENT DURATION; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; VISUAL DISORDER; WEIGHT GAIN;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HOSPITAL BED CAPACITY, 300 TO 499; HOSPITALS, PSYCHIATRIC; HOSPITALS, UNIVERSITY; HUMANS; INPATIENTS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PIPERAZINES; POLYPHARMACY; PRESCRIPTIONS, DRUG; QUINOLONES; RETROSPECTIVE STUDIES; SCHIZOPHRENIA;

EID: 45749084825     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2008.00233.x     Document Type: Article

References (36)

1. European Medicines Agency. Abilify. Scientific discussion. http://www.emeaeuropaeu/humandocs/PDFs/EPAR/abilify/089304en6.pdf/ 2005 [cited 22 April 2007].
2. El-Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database Syst Rev 2006 2 CD004578.
3. Travis MJ, Burns T, Dursun S, Fahy T, Frangou S, Gray R et al. Aripiprazole in schizophrenia: consensus guidelines. Int J Clin Pract 2005 Apr 59 : 485 95.
4. Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 2004 24 : 192 208.
5. Swainston HT, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 2004 64 : 1715 36.
6. El-Sayeh HG, Morganti C, Adams CE. Aripiprazole for schizophrenia. Systematic review. Br J Psychiatry 2006 Aug 189 : 102 8.
7. Hamann J, Kolbe G, Cohen R, Leucht S, Kissling W. How do psychiatrists choose among different antipsychotics? Eur J Clin Pharmacol 2005 61 : 851 4.
8. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003 64 : 663 7.
9. Edlinger M, Hausmann A, Kemmler G, Kurz M, Kurzthaler I, Walch T et al. Trends in the pharmacological treatment of patients with schizophrenia over a 12 year observation period. Schizophr Res 2005 77 : 25 34.
10. Barbui C, Nose M, Mazzi MA, Thornicroft G, Schene A, Becker T et al. Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries. Int Clin Psychopharmacol 2006 21 : 355 62.
11. Centorrino F, Eakin M, Bahk WM, Kelleher JP, Goren J, Salvatore P et al. Inpatient antipsychotic drug use in 1998, 1993, and 1989. Am J Psychiatry 2002 159 : 1932 5.
12. Bingefors K, Isacson D, Lindstrom E. Dosage patterns of antipsychotic drugs for the treatment of schizophrenia in Swedish ambulatory clinical practice - a highly individualized therapy. Nord J Psychiatry 2003 57 : 263 9.
13. Broekema WJ, de Groot, I, van Harten PN. Simultaneous prescribing of atypical antipsychotics, conventional antipsychotics and anticholinergics - a European study. Pharm World Sci 2007 29 : 126 30.
14. National Institute for Clinical Excellence. Guidance on the Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia, 43. National Institute for Clinical Excellence, London, 2002.
15. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Scizophrenia, 2nd edn. APA, Arlington, VA, 2004.
16. Lehman AF, Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB, Goldberg R et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull 2004 30 : 193 217.
17. Glenthøj B, Peacock L, Fink-Jensen A, Lublin H. Guidance on the Treatment with Antipsychotic Drugs [Retningslinjer for behandling med antipsykotika]. Sundhedsfaglige Raad i Psykiatri i Koebenhavns Amt og H:S, Copenhagen, Denmark, 2007.
18. Faries D, scher-Svanum H, Zhu B, Correll C, Kane J. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 2005 5 : 26.
19. Morrato EH, Dodd S, Oderda G, Haxby DG, Allen R, Valuck RJ. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid Population, 1998-2003. Clin Ther 2007 29 : 183 95.
20. Biancosino B, Barbui C, Marmai L, Dona S, Grassi L. Determinants of antipsychotic polypharmacy in psychiatric inpatients: a prospective study. Int Clin Psychopharmacol 2005 20 : 305 9.
21. Haw C, Stubbs J. Combined antipsychotics for 'difficult-to-manage' and forensic patients with scizophrenia: reasons for prescribing and perceived benefits. Psychiatr Bull 2003 27 : 449 52.
22. Ito H, Koyama A, Higuchi T. Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription. Br J Psychiatry 2005 187 : 243 7.
23. McCue RE, Waheed R, Urcuyo L. Polypharmacy in patients with schizophrenia. J Clin Psychiatry 2003 64 : 984 9.
24. Stahl SM, Grady MM. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr Med Chem 2004 11 : 313 27.
25. Waddington JL, Youssef HA, Kinsella A. Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 1998 173 : 325 9.
26. Joukamaa M, Heliovaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V. Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry 2006 188 : 122 7.
27. Henderson DC, Kunkel L, Nguyen DD, Borba CP, Daley TB, Louie PM et al. An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand 2006 113 : 142 7.
28. WHO Collaborating Centre for Drug Statistics Methodology. http://www.whoccno/atcddd/ 2007 [cited 8 June 2007].
29. Bristol-Meyer Squibb. Abilify. Summary of Product characteristics. http://www.emeaeuropaeu/htms/human/epar/a.htm/ 2007 [cited 21 May 2007].
30. Kinon BJ, Ahl J, Stauffer VL, Hill AL, Buckley PF. Dose response and atypical antipsychotics in schizophrenia. CNS Drugs 2004 18 : 597 616.
31. Molden E, Lunde H, Lunder N, Refsum H. Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients. Ther Drug Monit 2006 28 : 744 9.
32. 3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 2002 27 : 248 59.
33. Cutler AJ, Marcus RN, Hardy SA, O'Donnell A, Carson WH, McQuade RD. The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia. CNS Spectr 2006 11 : 691 702.
34. Crossman AM, Lindenmayer JP. Tolerability of high-dose aripiprazole in treatment-refractory schizophrenic patients. J Clin Psychiatry 2006 67 : 1158 9.
35. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 353 : 1209 23.
36. Ascher-Svanum H, Zhu B, Faries D, Landbloom R, Swartz M, Swanson J. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry 2006 6 : 8.